An official website of the United States government
Home
Name
GEM-CAP
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for GEM-CAP
Name
Alternate Names
Gemcitabine Hydrochloride
Gemzar
LY 188011
LY-188011
LY188011 hydrochloride
Gemcitabine HCL
Inlexzo intravesical system
Abbreviations
None
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
613327
Primary Site
Histology
None
Remarks
FDA approved for breast. ovarian, pancreas, NSC lung
Gemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.
On September 9, 2025, the FDA approved gemcitabine intravesical system (Inlexzo) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Gemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.
On September 9, 2025, the FDA approved gemcitabine intravesical system (Inlexzo) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Coding
This drug should be coded
Name
Alternate Names
Ro 091978
Ro-09-1978
Ro-091978
Xeloda
Abbreviations
None
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
712807
Primary Site
Breast cancer
Colorectal cancer
Gastric, esophageal and gastroesophageal junction cancer
Pancreatic cancer
Histology
None
Remarks
None
Coding
This drug should be coded
